According to this article from Charlotte Housden, Head of the Biotechnology and Research Business Unit at Cambridge Cognition, there is increasing pressure on pharmaceutical companies to accelerate the development of safe and effective treatments whilst reducing the risk of failure and encouraging commercial drug differentiation. In response to this growing demand, Cambridge Cognition has developed two cloud computing products to test cognitive safety and tolerability in drug development.